Cerebral Venous Sinus Thrombosis

Cerebral venous sinus thrombosis is a rare but potentially devastating form of stroke (0.5–3% of all strokes) caused by thrombosis of the dural venous sinuses and/or cerebral veins, predominantly affecting young women of reproductive age. [1] It requires a high index of clinical suspicion due to its variable and often insidious presentation. The 2024 AHA Scientific Statement provides the most current evidence-based framework for diagnosis and management. [1]

• Headache is the cardinal symptom, present in ~90% of cases — typically diffuse, progressive over days to weeks, worsened by coughing, bending, or head movement [1-2]
• Ask about onset pattern: subacute (most common, >48 hours) vs. thunderclap (rare, <5%) [1-2]
• Characterize headache: vertex or bifrontal location is more specific; patients with migraine history can often distinguish CVST headache from their usual migraine [2]
• Seizures at presentation in 20–40% (usually focal); focal neurologic deficits in 20–50% [1]
• Visual symptoms: transient visual obscurations, diplopia (CN VI palsy), vision loss [1]
• Altered mental status or encephalopathy in up to 20% [1]
• Pregnancy/postpartum status, recent OCP use, recent infection, trauma, surgery, dehydration, cancer history [1-2]

• Thunderclap headache — mimics subarachnoid hemorrhage [1-2]
• Encephalopathy, coma, or rapidly declining GCS [1]
• New focal neurologic deficits (hemiparesis, aphasia) [2]
• Seizures, especially status epilepticus
• Papilledema with visual loss — suggests severe intracranial hypertension [3]
• Bilateral leg weakness (superior sagittal sinus thrombosis with parasagittal infarction) [2]
• Signs of herniation (pupil asymmetry, posturing, Cushing response)
• Concurrent thrombocytopenia — raises concern for VITT (vaccine-induced thrombotic thrombocytopenia) [2]

• Contributors/Causative agents:
  • Estrogen-containing oral contraceptives (increase odds ~8-fold) [1]
  • Hormone replacement therapy [1]
  • Tamoxifen, cisplatin, L-asparaginase, corticosteroids, epoetin alfa [2]
• Treatment medications:
  • Acute: LMWH (preferred) or unfractionated heparin — even in the presence of intracranial hemorrhage [1][4]
  • Transition: VKA (warfarin, INR 2.0–3.0) for 3–12 months, or DOACs (apixaban, rivaroxaban, dabigatran) as a reasonable alternative [1][5]
  • Seizure management: levetiracetam or other appropriate AED; avoid prophylactic AEDs without seizure occurrence [2]
  • ICP management: acetazolamide may be considered; glucocorticoids are NOT recommended [2]
• Contraindicated in VITT: Heparin products — use non-heparin anticoagulants (fondaparinux, argatroban, or DOACs) plus IVIG [2]

• Hydration is critical — dehydration is a recognized transient risk factor, especially in pediatric populations [1-2]
• If on warfarin: counsel regarding consistent vitamin K intake
• No specific dietary triggers, but adequate fluid intake should be emphasized during acute illness and postpartum period

• Neurologic: headache character/progression, vision changes, diplopia, weakness, numbness, speech difficulty, seizures, confusion
• Ophthalmologic: transient visual obscurations, blurred vision
• OB/GYN: pregnancy status, postpartum period, OCP/HRT use, menstrual history
• Hematologic: prior DVT/PE, easy bruising, family history of clotting disorders
• Infectious: recent head/neck infection, sinusitis, mastoiditis, otitis, meningitis, COVID-19 [1]
• Constitutional: fever, weight loss (malignancy screening)
• GI: inflammatory bowel disease symptoms

• Family history of thrombophilia (Factor V Leiden, prothrombin G20210A, protein C/S deficiency) [1-2]
• Family history of VTE events (DVT, PE, stroke at young age)
• Collateral from family regarding timeline of symptom onset, behavioral changes, seizure activity
• Social history: recent travel, immobilization, substance use
• Vaccination history (COVID-19 adenoviral vaccines and VITT) [1]

• Transient: Pregnancy/puerperium, OCP/estrogen use, dehydration, head/neck infection, COVID-19, trauma, neurosurgery, recent vaccination (adenoviral COVID vaccines) [1-2]
• Chronic/Permanent: Inherited thrombophilias (Factor V Leiden, prothrombin mutation, protein C/S deficiency, antithrombin III deficiency), antiphospholipid syndrome, JAK2 mutations, myeloproliferative disorders, malignancy, Behçet disease, inflammatory bowel disease, nephrotic syndrome, sickle cell disease [1-2]
• Synergistic risk: OCP use + obesity [1]
• Demographics: Female sex (3:1), age <55 years [1][6]

• Subarachnoid hemorrhage — thunderclap headache overlap; CT/LP to differentiate
• Idiopathic intracranial hypertension (pseudotumor cerebri) — headache + papilledema + CN VI palsy; CVST must be excluded before diagnosing IIH [3]
• Arterial ischemic stroke — typically conforms to arterial territory; CVST infarcts cross arterial boundaries
• Meningitis/encephalitis — fever, meningismus, CSF pleocytosis
• Brain abscess or tumor — mass effect, focal deficits
• Migraine — especially with aura; CVST headache is typically distinguishable [2]
• Eclampsia/preeclampsia — in pregnant/postpartum patients
• Posterior reversible encephalopathy syndrome (PRES)
• Intracerebral hemorrhage (primary) — hemorrhage not conforming to arterial territory should raise CVST suspicion [1]

• Prior VTE events (DVT, PE, prior CVST)
• Known thrombophilia or hypercoagulable state
• Malignancy (especially hematologic)
• Autoimmune/inflammatory conditions (Behçet, IBD, SLE)
• Pregnancy history, miscarriages (antiphospholipid syndrome)
• Recent surgeries, especially neurosurgical
• Sickle cell disease, polycythemia vera
• Iron deficiency anemia (emerging association) [7]

• Vital signs: Hypertension (Cushing response if herniation), bradycardia, fever (if infectious etiology)
• Neurologic exam:
  • Mental status: alertness, orientation, encephalopathy assessment
  • Cranial nerves: CN VI palsy (false localizing sign of raised ICP), visual field deficits [1][3]
  • Motor: hemiparesis (may be bilateral leg weakness with sagittal sinus thrombosis) [2]
  • Speech: aphasia (temporal lobe involvement via vein of Labbé) [2]
  • Seizure activity
• Fundoscopy: Papilledema — develops over days to weeks [2-3]
• Scalp: Edema, dilated scalp veins (superior sagittal sinus involvement) [3]
• Signs of underlying etiology: Oral ulcers (Behçet), joint swelling (autoimmune), lymphadenopathy (malignancy)

• D-dimer: Sensitivity ~94% at cutoff >500 μg/L; a negative D-dimer has high NPV (~94–99%) and can help exclude CVST in low-probability patients. Caveat: false negatives occur with isolated headache, chronic symptoms (>6 days), and limited sinus involvement [3][8-9]
• CBC with differential: Thrombocytopenia (VITT, DIC, HIT), polycythemia, leukocytosis
• Coagulation panel: PT/INR, aPTT, fibrinogen
• Comprehensive metabolic panel
• Thrombophilia workup (typically deferred to outpatient unless VITT suspected): Factor V Leiden, prothrombin G20210A, protein C/S, antithrombin III, antiphospholipid antibodies, JAK2 mutation, homocysteine [1-2]
• Anti-PF4 antibodies if VITT suspected [2]
• Pregnancy test in women of reproductive age
• ESR/CRP if infectious or inflammatory etiology suspected

• Non-contrast CT head: Often the first test; may be normal in up to 30% of cases. Look for:
  • Dense vessel/cord sign (hyperdense thrombus in vein/sinus) [1]
  • Dense triangle sign (hyperdense superior sagittal sinus) [1]
  • Hemorrhagic infarction not conforming to arterial territory
  • Bilateral parasagittal hypodensities [1]
• CT venography (CTV): Confirmatory test readily available in ED; shows filling defects ("empty delta sign"); high sensitivity and specificity [1]
• MRI/MRV: Gold standard per AHA — best for cortical vein thrombosis and parenchymal characterization. Contrast-enhanced MRV, GRE, or SWI sequences recommended for cortical vein thrombosis [1]
• When imaging is unnecessary: If clinical suspicion is low AND D-dimer is negative, CVST is very unlikely [8]
• Digital subtraction angiography: Reserved for cases where endovascular intervention is planned [1]

• CVT Clinical Prediction Score (Heldner et al.): Combines 6 variables — seizure (4 pts), known thrombophilia (4 pts), OCP use (2 pts), symptom duration >6 days (2 pts), worst headache ever (1 pt), focal deficit (1 pt). Combined with D-dimer >500 μg/L, achieves AUC of 0.937 [8]
• Lumbar puncture: May show elevated opening pressure; useful if meningitis is in the differential. Should be performed AFTER imaging to exclude mass effect
• Fundoscopic exam / optical coherence tomography for papilledema assessment
• EEG if seizures or subclinical seizure activity suspected

• ECG is not a primary diagnostic tool for CVST
• Obtain ECG to rule out cardiac arrhythmias (e.g., atrial fibrillation) as a cause of cardioembolic stroke in the differential
• No specific ECG findings are pathognomonic for CVST
• May identify concurrent conditions (e.g., right heart strain if concomitant PE)

CVST is a neurologic emergency that accounts for 0.5–3% of all strokes, with death or dependence occurring in 10–15% despite treatment. [1] The clinical course is unpredictable. Key prognostic factors associated with poor outcomes include advanced age, active cancer, decreased level of consciousness, and intracerebral hemorrhage. [1]

Clinical syndromes include: [10]

• Isolated headache syndrome (~25%) — most diagnostically challenging
• Raised ICP syndrome — headache, papilledema, CN VI palsy
• Stroke-like syndrome — focal deficits ± seizures
• Encephalopathy syndrome — altered consciousness, diffuse deficits

Most patients (~80%) achieve good functional recovery, but chronic sequelae (fatigue, headache, cognitive/mood disturbances, epilepsy) are common and impact quality of life. [11]

Acute Stabilization

• ABCs, IV access, continuous monitoring
• Seizure management with levetiracetam or benzodiazepines for active seizures
• ICP management: head of bed elevation, osmotic therapy if signs of herniation

Anticoagulation (cornerstone of treatment)

• LMWH (enoxaparin 1 mg/kg SC q12h) preferred over UFH in the acute phase [1][4]
• Intracranial hemorrhage is NOT a contraindication to anticoagulation in CVST [1][12]
• Transition to oral anticoagulation after stabilization:
  • VKA (warfarin, target INR 2.0–3.0) for 3–12 months depending on etiology [1]
  • DOACs (apixaban, rivaroxaban, dabigatran) are a reasonable alternative based on emerging evidence showing comparable safety and efficacy [1][5]
  • Lead-in parenteral anticoagulation for 5–15 days before transitioning to oral agents [1]
• Indefinite anticoagulation for recurrent VTE, severe thrombophilia, or antiphospholipid syndrome [1]

VITT-specific treatment: Avoid all heparin products; use IVIG + non-heparin anticoagulant (fondaparinux, argatroban, or DOAC) [2]

Refractory cases

• Endovascular therapy (mechanical thrombectomy ± local fibrinolysis) reserved for neurological deterioration despite maximal anticoagulation [1][13]
• Decompressive craniectomy is a lifesaving procedure for patients with signs of herniation [1]

• All confirmed CVST patients require admission — typically to a stroke unit or neuro-ICU [14]
• ICU admission criteria: Decreased level of consciousness, large hemorrhagic infarction, status epilepticus, signs of herniation, need for ICP monitoring
• Neurology consultation is mandatory
• Neurosurgery consultation for patients with mass effect, herniation, or consideration of decompressive craniectomy [1]
• Interventional neuroradiology consultation for refractory cases being considered for endovascular therapy [1]
• Hematology consultation for thrombophilia workup and anticoagulation management

Follow-up timing

• Neurology follow-up within 1–2 weeks of discharge
• Repeat neuroimaging (CTV or MRV) at 3–6 months to assess recanalization, though the role of recanalization in guiding anticoagulation duration remains uncertain [1]
• Hematology follow-up for thrombophilia results and anticoagulation duration decisions
• Ophthalmology if papilledema present

Return precautions — counsel patients to return immediately for:

• Worsening or new-onset headache
• New weakness, numbness, speech difficulty, or vision changes
• Seizures
• Altered mental status or confusion
• Signs of bleeding (on anticoagulation): blood in stool/urine, excessive bruising, prolonged bleeding

Patient counseling

• Discuss anticoagulation compliance and bleeding precautions
• Discontinue estrogen-containing contraceptives — discuss alternative contraception [1]
• Expected recovery: ~80% achieve functional independence, but chronic symptoms (headache, fatigue, cognitive difficulties) are common and may persist [11]
• Recurrence risk: increased risk of recurrent CVT and other VTE; highest in those with cancer, antiphospholipid syndrome, prior VTE, or idiopathic events [11]

1. Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association. — Saposnik G, Bushnell C, Coutinho JM, et al. Stroke. 2024.

2. Cerebral Venous Thrombosis. — Ropper AH, Klein JP. The New England Journal of Medicine. 2021.

3. Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/­American Stroke Association. — Saposnik G, Barinagarrementeria F, Brown RD, et al. Stroke. 2011.

4. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. — Lansberg MG, O'Donnell MJ, Khatri P, et al. Chest. 2012.

5. Direct Oral Anticoagulants Versus Vitamin K Antagonists for Cerebral Venous Thrombosis (DOAC-CVT): An International, Prospective, Observational Cohort Study. — van de Munckhof A, van Kammen MS, Tatlisumak T, et al. The Lancet. Neurology. 2025.

6. Pathophysiology, Diagnosis and Management of Cerebral Venous Thrombosis: A Comprehensive Review. — Ranjan R, Ken-Dror G, Sharma P. Medicine. 2023.

7. Clinico-Radiological Profile of CVT Patients and Its Correlation With D-Dimer. — Pathak A, Nath Chaurasia R, Kumar Singh V, et al. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 2020.

8. Prediction of Cerebral Venous Thrombosis With a New Clinical Score and D-Dimer Levels. — Heldner MR, Zuurbier SM, Li B, et al. Neurology. 2020.

9. D-Dimer Testing in the Diagnosis of Cerebral Vein Thrombosis: A Systematic Review and a Meta-Analysis of the Literature. — Dentali F, Squizzato A, Marchesi C, et al. Journal of Thrombosis and Haemostasis : JTH. 2012.

10. Cerebral Venous Thrombosis: A Practical Review. — Borhani-Haghighi A, Hooshmandi E. Postgraduate Medical Journal. 2024.

11. Current Management of Cerebral Venous Thrombosis. — Field TS, Fragata I. Stroke. 2026.

12. Cerebral Venous Thrombosis. — Aamodt AH, Skattør TH. Seminars in Thrombosis and Hemostasis. 2022.

13. Fibrinolytic Therapy for Thromboembolic Diseases: Approved Indications and Future Directions. — Rashedi S, Leyva H, Hamade N, et al. Journal of the American College of Cardiology. 2025.

14. Cerebral Venous Thrombosis: Diagnosis and Management in the Emergency Department Setting. — Spadaro A, Scott KR, Koyfman A, Long B. The American Journal of Emergency Medicine. 2021.